131 related articles for article (PubMed ID: 2738264)
1. Cardioprotective effects of various class I antiarrhythmic drugs in canine hearts.
Hanaki Y; Sugiyama S; Hieda N; Taki K; Hayashi H; Ozawa T
J Am Coll Cardiol; 1989 Jul; 14(1):219-24. PubMed ID: 2738264
[TBL] [Abstract][Full Text] [Related]
2. [The effect of flecainide on 2 hour occlusion-induced myocardial damages in dog].
Sugiyama S; Hieda N; Ozawa T; Fukushima A; Ogawa T; Hanaki Y
Kokyu To Junkan; 1989 Apr; 37(4):443-7. PubMed ID: 2500690
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effect of bepridil on ischemic myocardial damages in dogs.
Hanaki Y; Sugiyama S; Hieda N; Taki K; Ozawa T
Arch Int Pharmacodyn Ther; 1989; 299():221-31. PubMed ID: 2789024
[TBL] [Abstract][Full Text] [Related]
4. Effects of antiarrhythmic agents classified as class III group on ischaemia-induced myocardial damage in canine hearts.
Sano T; Sugiyama S; Taki K; Hanaki Y; Shimada Y; Ozawa T
Br J Pharmacol; 1990 Mar; 99(3):577-81. PubMed ID: 2331583
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and antiarrhythmic effects of three calcium channel antagonists in ischemic canine hearts.
Ito T; Ogawa T; Satake T; Hieda N; Sugiyama S; Ozawa T
Clin Ther; 1989; 11(4):461-71. PubMed ID: 2776164
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective and antiarrhythmic effects of beta-blockers, propranolol, bisoprolol, and nipradilol in a canine model of regional ischemia.
Ogawa T; Hieda N; Sugiyama S; Ito T; Satake T; Ozawa T
Heart Vessels; 1989; 5(1):10-6. PubMed ID: 2573596
[TBL] [Abstract][Full Text] [Related]
7. Antiarrhythmic effects of combined application of class I antiarrhythmic drugs; addition of low-dose mexiletine-enhanced antiarrhythmic effects of disopyramide and aprindine in various-rate canine ventricular tachycardias.
Awaji T; Hashimoto K
J Cardiovasc Pharmacol; 1993 Jun; 21(6):960-6. PubMed ID: 7687723
[TBL] [Abstract][Full Text] [Related]
8. Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide.
Xue YX; Arita J; Aye NN; Hashimoto K
Naunyn Schmiedebergs Arch Pharmacol; 1998 Dec; 358(6):649-56. PubMed ID: 9879724
[TBL] [Abstract][Full Text] [Related]
9. Effect of a novel thromboxane A2 synthetase inhibitor on ischemia-induced mitochondrial dysfunction in canine hearts.
Ogawa T; Hieda N; Sugiyama S; Toki Y; Ito T; Ogawa K; Satake T; Ozawa T
Arzneimittelforschung; 1988 Feb; 38(2):228-30. PubMed ID: 3370069
[TBL] [Abstract][Full Text] [Related]
10. The effect of cibenzoline on myocardial damages in dogs.
Taki K; Sugiyama S; Hieda N; Hanaki Y; Sano T; Shimada Y; Ozawa T
Arzneimittelforschung; 1989 Mar; 39(3):325-8. PubMed ID: 2757658
[TBL] [Abstract][Full Text] [Related]
11. Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
Komori S; Sawanobori T; Tamura K; Kane KA; Parratt JR
Jpn J Pharmacol; 1994 Jul; 65(3):193-200. PubMed ID: 7799519
[TBL] [Abstract][Full Text] [Related]
12. Effects of pentisomide and E-4031 on canine atrial flutter due to reentry: a comparative study with disopyramide and propafenone.
Inoue H; Yamashita T; Usui M; Nozaki A; Saihara S; Sugimoto T
J Cardiovasc Pharmacol; 1991 Jul; 18(1):137-43. PubMed ID: 1719282
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of the antiarrhythmic effect of drugs on canine ventricular arrhythmias by the determination of minimum effective plasma concentrations.
Hashimoto K; Shibuya T; Satoh H; Imai S
Jpn Circ J; 1983 Jan; 47(1):92-7. PubMed ID: 6827775
[TBL] [Abstract][Full Text] [Related]
14. SC-36602, a new antiarrhythmic agent: comparison of its cardiovascular profile with that of other antiarrhythmic drugs.
Frederick LG; Hatley FR; McDonald SJ; Stamm MH; Garthwaite SM
J Cardiovasc Pharmacol; 1988 Jun; 11(6):657-66. PubMed ID: 2457760
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and morphological changes in myocardium during coronary occlusion and reperfusion in canine hearts: effects of propranolol on myocardial damage.
Ogawa T; Sugiyama S; Hieda N; Ito T; Satake T; Ozawa T
Cardiovasc Res; 1989 May; 23(5):417-23. PubMed ID: 2611809
[TBL] [Abstract][Full Text] [Related]
16. Is the sarcolemmal or mitochondrial K(ATP) channel activation important in the antiarrhythmic and cardioprotective effects during acute ischemia/reperfusion in the intact anesthetized rabbit model?
Das B; Sarkar C
Life Sci; 2005 Jul; 77(11):1226-48. PubMed ID: 15964023
[TBL] [Abstract][Full Text] [Related]
17. Effects of bidisomide (SC-40230), a new class I antiarrhythmic agent, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats; comparison with mexiletine and disopyramide.
Komori S; Sano S; Li BH; Matsumura K; Naitoh A; Mochizuki S; Ishihara T; Watanabe A; Umetani K; Ijiri H
Heart Vessels; 1995; 10(1):7-11. PubMed ID: 7537263
[TBL] [Abstract][Full Text] [Related]
18. Frequency dependent effects of class I antiarrhythmic agents studied in patients with implanted pacemakers.
Takanaka C; Lee JK; Nonokawa M; Sugiyama T; Yame S
Pacing Clin Electrophysiol; 1994 Nov; 17(11 Pt 2):2100-5. PubMed ID: 7845825
[TBL] [Abstract][Full Text] [Related]
19. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiologic and hemodynamic effects of propafenone, a new antiarrhythmic agent, on the anesthetized, closed-chest dog: comparative study with lidocaine.
Karagueuzian HS; Katoh T; McCullen A; Mandel WJ; Peter T
Am Heart J; 1984 Mar; 107(3):418-24. PubMed ID: 6695682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
